Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. In this study, we evaluated the long-term efficacy, safety, and tolerability of monthly and quarterly fre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Headache Pain
Main Authors: Ashina, Messoud, Cohen, Joshua M., Galic, Maja, Campos, Verena Ramirez, Barash, Steve, Ning, Xiaoping, Kessler, Yoel, Janka, Lindsay, Diener, Hans-Christoph
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Milan 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8272284/
https://ncbi.nlm.nih.gov/pubmed/34246226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-021-01279-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados